pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development)

Transcription

1 Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group Q results Diagnostics Foreign exchange rate information 1

2 Changes to the development pipeline Q update New to Phase I New to Phase II New to New to Registration 1AI RG7813 CEA IL2v + PD-L1MAb - solid tumors 1 NME (Trophos acquisition) RG6083 olesoxime - SMA 1 NME (shown to reflect upcoming submission) RG7853 alectinib - ALK-mut. pos. NSCLC 2L 1 AI (previous P2 in solid tumors split out) RG7604 taselisib - NSCLC sq. 2L 1 NME RG7604 taselisib - ER+/HER2- neg mbc 7 AIs RG7413 etrolizumab - Crohn s disease RG7446 PD-L1 MAb Dx-pos. patients - NSCLC sq. 1L RG7446 PD-L1 MAb Dx-pos. patients - NSCLC non-sq. 1L RG7446 PD-L1 MAb + chemo - NSCLC sq. 1L RG7446 PD-L1 MAb + chemo - NSCLC non sq. 1L RG7446 PD-L1 MAb + chemo +/- Avastin - NSCLC non sq. 1L RG7853 alectinib Alk-mut.pos. - NSCLC 1L Removed from Phase I Removed from Phase II Removed from 2 NMEs RG7410 TAAR1 ago - schizophrenia RG7342 mglu5 PAM - schizophrenia 2 NMEs RG7790 setrobuvir HCV RG7321 pictilisib solid tumors 1 AI RG435 Avastin - NSCLC adj. Removed from Registration 1 AI following US approval RG3645 Lucentis - diabetic retinopathy 1 AI following EU approval RG435 Avastin cervical cancer Status as of April 22,

3 Roche Group development pipeline Oncology Phase I (31 NMEs + 12 AIs) Other disease areas RG6016 LSD1 inh AML RG autoimmune diseases RG6047 SERD (2) ER+(HER2-neg) mbc RG inflammatory diseases RG6061 HIF1 alpha LNA solid tumors RG6080 DBO β-lactamase inh bact. infections RG6078 IDO inh solid tumors RG infectious diseases RG7116 lumretuzumab (HER3 MAb) solid tumors RG7795 TLR7 agonist HBV RG7155 emactuzumab (CSF-1R) + PDL1 s.tumors RG7641 aldosterone synth inh met. diseases RG7304 Raf & MEK dual inh solid tumors RG7203 PDE10A inh schizophrenia RG7388 idasanutlin (MDM2 ant) s. & hem tumors RG7345 TAU MAb Alzheimer s RG7446 PD-L1 MAb solid tumors RG7893 Nav1.7 inh pain RG7446 PD-L1+Zelboraf+/-cobimetinib melanoma RG7800 SMN2 splicer spinal muscular atrophy RG7446 PD-L1+Avastin+chemo solid tumors RG7935 a-synuclein MAb Parkinson's Disease RG7446 PD-L1 MAb+cobimetinib solid tumors RG3645 Lucentis sust. deliv. AMD/RVO/DME RG7446 PD-L1 MAb+ipi/IFN solid tumors RG7716 VEGF-ANG2 MAb wamd RG7446 RG7446 PD-L1 MAb+Tarceva PD-L1 MAb+Gazyva NSCLC EGFR+ lymphoma New Molecular Entity (NME) Additional (AI) RG7450 RG7597 RG7601 RG7601 RG7741 RG7775 RG7787 RG7802 RG7813 Steap 1 ADC prostate ca. duligotuzumab (HER3/EGFR)+ cobi s. tum. venetoclax heme indications venetoclax+gazyva CLL CLL ChK1 inh solid tum & lymphoma MDM2 (4) IV prodrug AML MSLN PE cfp solid tumors CEA CD3 TCB solid tumors CEA IL2v solid tumors Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other RG-No Roche Genentech managed CHU Chugai managed RG7813 CEA IL2v + PD-L1 MAb solid tumors RG7841 ADC solid tumors RG7842 ERK inh solid tumors RG7876 CD40 imab+pd-l1 MAb solid tumors RG7882 ADC ovarian ca RG7888 OX40 MAb solid tumors 3 Status as of April 22, 2015

4 Roche Group development pipeline Phase II (22 NMEs + 14 Als) (9 NMEs + 27 Als) Registration (1 NME + 2 Als) RG435 RG3502 RG6013 RG6046 RG7155 RG7221 RG7421 RG7440 RG7446 RG7446 RG7446 RG7596 RG7601 RG1569 RG3637 RG6062 CHU RG7227 RG7745 RG1577 RG1678 FIXa/FX bispecific MAb ipatasertib PD-L1 MAb +Avastin polatuzumab vedotin venetoclax Actemra danoprevir sembragiline (MAO-B inh) bitopertin solid tumors hem tumors systemic sclerosis lebrikizumab Esbriet SSc interstitial idiopathic pulmonary lung disease fibrosis IL-31R MAb Flu A MAb LptD antibiotic hemophilia A PD-L1 MAb NSCLC 2/3L RCC ADC RG7599 lifastuzumab vedotin Pt-resist. OC RG7601 RG7601 RG7604 RG7604 RG7686 RG7853 RG3637 RG7929 RG7697 CHU RG1662 Avastin+Tarceva Kadcyla SERD emactuzumab (CSF-1R) PVNS/s. tumors vanucizumab (Ang2-VEGF MAb) cobimetinib+paclitaxel PD-L1 MAb bladder cancer 1/2L RCC venetoclax venetoclax+rituxan taselisib taselisib glypican-3 MAb alectinib lebrikizumab GIP/GLP-1 dual ago URAT 1 inh GABRA5 NAM EGFR mut+ NSCLC HER2+ NSCLC ER+(HER2-neg) mbc mcrc TNBC 17p del CLL rel/ref DLBCL FL rel/ref NSCLC sq 2L ER+(HER2-neg) BC neoadj liver cancer ALK+ NSCLC 2L IPF atopic dermatitis HCV influenza antibacterial type 2 diabetes gout Alzheimer s Down Syndrome obsessive compulsive dis. RG435 RG1273 RG1273 RG1273 RG3502 RG3502 RG3502 RG3502 RG3502 RG7159 RG7159 RG7159 RG7204 RG7446 RG7601 RG7601 RG7853 RG1569 RG3637 RG7413 Avastin Kadcyla +/- Perjeta Gazyva Actemra glioblastoma 1L RG435 1 Avastin ovarian cancer 1L RG435 1 Avastin rel. ovarian ca. Pt-sensitive RG7446 NSC RG7446 RG7446* RG7446* RG7446* RG7446 RG7604 RG7413 HER2+ mbc 1L DLBCL1L large-vessel vasculitis RG7929 RG6083 olesoxime spinal muscular atrophy RG1450 gantenerumab Alzheimer s RG7090 basimglurant TRD RG1594 ocrelizumab RMS RG7314 V1 receptor antag autism RG1594 ocrelizumab PPMS RG7412 crenezumab Alzheimer s RG7417 lampalizumab geographic atrophy CHU CHU Perjeta+Herceptin Perjeta+Herceptin Perjeta+Herceptin HER2+gastric ca 1L Kadcyla Kadcyla Kadcyla + Perjeta Kadcyla + Perjeta Gazyva Gazyva Zelboraf PD-L1 MAb PD-L1+chemo PD-L1 MAb venetoclax+rituxan venetoclax+gazyva alectinib Actemra lebrikizumab etrolizumab IL-6R MAb HER2+ mbc 2L HER2+ BC adj HER2+ gastric cancer 2L HER2+ BC adj HER2+ BC adj HER2+ BC neoadj inhl rituximab-ref follicular lymphoma 1L melanoma adj NSCLC 2L NSCLC non-sq 1L PD-L1+chemo+Avastin NSCLC non-sq 1L PD-L1+chemo PD-L1 MAb Dx+ PD-L1 MAb Dx+ taselisib etrolizumab NSCLC sq 1L NSCLC sq 1L NSCLC non-sq 1L bladder cancer 2L CLL rel/ref CLL 1L ER+(HER2-neg) mbc ALK+ NSCLC 1L giant cell arteritis severe asthma ulcerative colitis Crohn s disease neuromyelitis optica RG105 MabThera SC RG Perjeta HER2+ BC neoadj RG7421 cobimetinib + Zelboraf m. melanoma 1 US only : FDA submission decision pending 2 Approved in US, submitted in EU * FPI imminent New Molecular Entity (NME) Additional (AI) Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other CLL RG-No Roche Genentech managed CHU Chugai managed RG105 MabThera is branded as Rituxan in US and Japan RG1569 Actemra is branded as RoActemra in EU RG7159 Gazyva is branded as Gazyvaro in EU Status as of April 22,

5 NME submissions and their additional indications Projects currently in phase 2 and 3 GABRA5 NAM (RG1662) Down syndrome bitopertin (RG1678) obsessive compulsive dis. taselisib ( RG7604) ER+(HER2-neg) BC neoadj basimglurant (RG7090) depression New Molecular Entity Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other SERD (RG6046) ER+(HER2-neg) mbc FIXa/FX bispecific MAb (RG6013) hemophilia A emactuzumab (RG7155) PVNS and solid tumors vanucizumab (RG7221) colorectal cancer taselisib ( RG7604) NSCLC sq 2L PDL1 MAb (RG7446) NSCLC sq 1L (Dx+) PDL1 MAb (RG7446) NSCLC non-sq 1L (Dx+) PDL1 MAb (RG7446)+ chemo NSCLC sq 1L V1 receptor antag (RG7314) autism crenezumab (RG7412) Alzheimer s sembragiline (RG1577) Alzheimer s gantenerumab (RG1450) Alzheimer s ipatasertib (RG7440) solid tumors PDL1 MAb (RG7446)+ chemo NSCLC non-sq 1L lebrikizumab (RG3637) idiopathic pulmonary fibrosis ocrelizumab (RG1594) PPMS polatuzumab vedotin (RG7596) heme tumors PDL1 MAb (RG7446)+chemo + Avastin NSCLC non-sq 1L etrolizumab (RG7413) Crohn s disease lebrikizumab (RG3637) severe asthma lifastuzumab (RG7599) Pt resistant OC cobimetinib+paclitaxel TNBC etrolizumab (RG7413) ulcerative colitis PDL-1 MAb (RG7446) bladder cancer olesoxime (RG6083) SMA taselisib (RG7604) HER2 neg ER+ mbc venetoclax (RG7601) + Rituxan FL rel/ref danoprevir* (RG7227) HCV ocrelizumab (RG1594) RMS PD-L1 MAb (RG7446) NSCLC 2/3L PDL-1 MAb (RG7446) combo Avastin RCC glypican-3 MAb (RG7686) liver cancer venetoclax (RG7601) + Gazyva CLL 1L Flu A MAb (RG7745) influenza alectinib (RG7853) Alk+ NSCLC 2L venetoclax (RG7601) CLL rel/ref alectinib (RG7853) Alk+ NSCLC 1L lampalizumab (RG7417) geographic atrophy venetoclax (RG7601) DLBCL LptD antibiotic (RG7929) antibacterial and beyond * lead market China Unless stated otherwise, submissions are planned to occur in US and EU Status as of April 22,

6 Submissions of additional indications for existing products Projects currently in phase 2 and 3 Gazyva inhl rituximab refractory *Avastin (US) ovarian cancer 1 st L *Avastin (US) rel. ovarian ca. Pt-sens Zelboraf melanoma adj. Kadcyla HER2+ NSCLC Avastin +Tarceva(EU) EGFR mut+ NSCLC Gazyva DLBCL 1L Kadcyla+Perjeta HER2+ BC neoadj Avastin (US) GBM Perjeta + Herceptin HER2+ mbc 2L Kadcyla+Perjeta HER2+ BC adj Kadcyla +/- Perjeta HER2+ mbc 1L Perjeta + Heceptin HER2+ BC adj Gazyva follicular lymphoma 1L Kadcyla HER2+ BC adj Kadcyla HER2+ gastric cancer 2L Actemra giant cell arteritis Perjeta+Herceptin HER2+ gastric cancer 1L Actemra systemic sclerosis and beyond * approved in EU Unless stated otherwise, submissions are planned to occur in US and EU Status as of April 22, 2015 Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other NME 6

7 Major granted and pending approvals 2015 Approved Pending approvals US Lucentis diabetic retinopathy February 2015 cobimetinib + Zelboraf m. melanoma Filed December 2014 Avastin cervical cancer April 2015 Perjeta HER2+ BC neoadj Filed September 2014 EU cobimetinib + Zelboraf m. melanoma Filed September 2014 MabThera SC CLL Filed November 2014 Japan-Chugai Xeloda gastric cancer adj Filed December 2014 Bonviva osteoporosis (oral) Filed February 2015 Status as of April 22, 2015 Oncology Immunology Infectious Diseases CardioMetabolism Neuroscience Ophthalmology Other NME 7

8 Cancer immunotherapy pipeline overview Phase I (7 NMEs + 9 AIs) Phase II (1NME + 3 Als) (1NME + 6AIs) RG6078 IDO inh solid tumors RG7155 emactuzumab (CSF-1R) PVNS/s. tumors RG7446 PD-L1 MAb NSCLC 2L RG7155 emactuzumab (CSF-1R) + PDL1 s.tumors RG7446 PD-L1 MAb NSCLC 2/3L RG7446 PD-L1+chemo NSCLC non-sq 1L RG7446 RG7446 RG7446 PD-L1 MAb solid tumors PD-L1+Zelboraf+/-cobimetinib melanoma PD-L1+Avastin+chemo solid tumors RG7446 RG7446 PD-L1 MAb bladder cancer 1/2L RCC NSC RG7446 PD-L1 MAb +Avastin RCC RG7446 RG7446 PD-L1+chemo+Avastin NSCLC non-sq 1L PD-L1+chemo NSCLC sq 1L PD-L1 MAb Dx+ NSCLC sq 1L RG7446 PD-L1 MAb+cobimetinib solid tumors RG7446 PD-L1 MAb Dx+ NSCLC non-sq 1L RG7446 PD-L1 MAb+ipi/IFN solid tumors RG7446 PD-L1 MAb bladder cancer 2L RG7446 PD-L1 MAb+Tarceva NSCLC EGFR+ RG7446 PD-L1 MAb+Gazyva lymphoma RG7802 RG7813 CEA CD3 TCB CEA IL2v solid tumors solid tumors RG7813 CEA IL2v + PD-L1 MAb solid tumors RG7876 CD40 imab+pd-l1 MAb solid tumors RG7888 OX40 MAb solid tumors *INCB *CDX PD-L1 MAb + IDO inh solid tumors PD-L1 MAb + varlilumab solid tumors *external collaborations: INCB- Incyte INCB024360; CDX Celldex CD27 MAb Status as of April 22,

9 Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group Q results Diagnostics Foreign exchange rate information 9

10 Avastin Ovarian cancer clinical development programme Phase/study GOG-0218 Front-line metastatic ovarian cancer ICON7 # of patients N=1,873 N=1,528 ARM A: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent placebo followed by placebo alone for up to 22 cycles (15 months) ARM B: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by placebo alone for up to 22 cycles (15 months) ARM C: Paclitaxel and carboplatin for 6 cycles plus 5 cycles of concurrent Avastin followed by Avastin alone for up to 22 cycles (15 months) Avastin dose 15 mg/kg q3 weeks 7.5 mg/kg q3 weeks ARM A: Paclitaxel and carboplatin for 6 cycles ARM B: Paclitaxel and carboplatin plus concurrent Avastin for 6 cycles followed by Avastin alone for up to 18 cycles (12 months) Progression-free survival Progression-free survival Status Study met its primary in Q Data presented at ASCO 2010 and 2011 Results: NEJM 2011 Dec 29;365(26): Study met its primary Q Data presented at ESMO 2010 and ASCO 2011 Results: NEJM 2011 Dec 29;365(26): OS data presented at ECC 2013 EMA approval granted Q Re-evaluate FDA submission in 2015 ASCO=American Society of Clinical Oncology; ESMO=European Society for Medical Oncology 10

11 Avastin Cervical and brain cancer clinical development programmes Stage IVB, recurrent or persistent cervical cancer Newly diagnosed glioblastoma Phase/study GOG-240 AVAglio # of patients N=452 N=920 Avastin dose ARM A: Paclitaxel, cisplatin ARM B: Paclitaxel, cisplatin plus Avastin ARM C: Paclitaxel, topotecan ARM D: Paclitaxel, topotecan plus Avastin 15 mg/kg q3 weeks Overall survival Status Study met its primary Q Results published in NEJM Feb. 2014; 370(8): Filed globally Q FDA approval granted Q Approved in EU Q ARM A: Concurrent radiation and temozolomide plus placebo; followed by maintenance TMZ plus placebo for 6 cycles; then placebo until disease progression ARM B: Concurrent radiation and TMZ plus Avastin; followed by maintenance TMZ plus Avastin for 6 cycles; then Avastin (15mg/kg q3 weeks) monotherapy until disease progression 10 mg/kg q2 weeks or 15 mg/kg q3 weeks Progression-free survival Overall survival Co-primary of PFS met Q Overall survival data presented at ASCO 2013 Filed in EU Q Negative CHMP opinion Q US filing pending TMZ=temozolomide ASCO=American Society of Clinical Oncology 11

12 Avastin Lung, breast and ovarian cancer development programmes Adjuvant lung cancer First-line HER2-negative metastatic breast cancer Relapsed platinum-sensitive ovarian cancer Phase/study ECOG 1505 MERiDiAN OCEANS # of patients N=1,500 N=480 N=484 Avastin dose ARM A: Cisplatin plus vinorelbine, docetaxel, gemcitabine or pemetrexed ARM B: Cisplatin plus vinorelbine, docetaxel, gemcitabine or pemetrexed plus Avastin up to 12 months ARM A: Paclitaxel + Avastin ARM B: Paclitaxel + Placebo ARM A: Carboplatin, gemcitabine, and concurrent placebo for 6-10 cycles, followed by placebo alone until disease progression ARM B: Carboplatin, gemcitabine, and concurrent Avastin for 6-10 cycles, followed by Avastin alone until disease progression. 15 mg/kg q3 weeks 10 mg/kg q2 weeks 15 mg/kg q3 weeks Overall survival Status Recruitment completed Q Trial stopped for futility Q SGO=Society of Gynecologic Oncology PFS in ITT PFS in patients with high plasma VEGF-A Co-primary s met Q Data to be presented in 2015 Progression-free survival Study met its primary Q EMA approval granted Q Final data presented at SGO 2014 Re-evaluate FDA submission in

13 Erivedge A novel small molecule inhibitor of the hedgehog signaling pathway Locally advanced or metastatic basal cell carcinoma Idiopathic pulmonary fibrosis Phase/study Phase II STEVIE Phase II # of patients N=1,200 N=129 Single ARM: 150 mg Erivedge orally once daily ARM A: Erivedge 150mg daily ARM B: placebo Safety: Incidence of adverse events Change in forced vital capacity (FVC) Status FPI Q FPI pending in anticipation of trial design amendment to incorporate new standard of care Esbriet In collaboration with Curis 13

14 Esbriet Small molecule with activity in fibrotic diseases Systemic sclerosis-related interstitial lung disease (SSc-ILD) Phase/study Phase II LOTUSS # of patients N=63 Open-label, randomized, parallel-group, safety and tolerability study 2 week vs. 4 week dose titration regimens Safety Status LPI Q Data to be presented at ATS 2015 ATS=Annual Meeting of American Thoracic Society 14

15 Gazyva/Gazyvaro Type II, glycoengineered anti-cd20 monoclonal antibody Previously untreated or relapsed/refractory chronic lymphocytic leukemia Diffuse large B-cell lymphoma (DLBCL) Phase/study GREEN GOYA # of patients N=800 N=1,418 Single-arm cohort study: Gazyva alone or in combination with different chemotherapy regimens (FC, Bendamustin or Clb), investigation of different strategies to reduce IRRs ARM A: Gazyva 1000mg IV plus CHOP ARM B: MabThera/Rituxan plus CHOP Safety in combination with different chemotherapy regimens Progression-free survival Status FPI Q Initial safety data presented at ASH 2014 Recruitment completed Q Trial continues after interim analysis in 2015 Final data expected in 2016 In collaboration with Biogen Idec ASH=American Society of Hematology 15

16 Gazyva/Gazyvaro Type II, glycoengineered anti-cd20 monoclonal antibody Indolent non-hodgkin s lymphoma MabThera/Rituxan refractory Front-line indolent non-hodgkin s lymphoma Phase/study GADOLIN Induction and maintenance study GALLIUM Induction and maintenance study # of patients N=411 N=1,401 ARM A: Gazyva 1000mg IV plus bendamustine followed by Gazyva mainteinance ARM B: bendamustine ARM A: Gazyva 1000mg IV plus chemotherapy followed by Gazyva maintenance ARM B: MabThera/Rituxan plus chemotherapy followed by MabThera/Rituxan maintenance Chemotherapy: For follicular lymphoma: CHOP, CVP or bendamustine For non-follicular lymphoma: physician s choice Progression-free survival Progression-free survival Status Trial stopped at interim for efficacy Q Data to be presented at ASCO 2015 Expect global filing in 2015 Recruitment completed Expect data in 2017 In collaboration with Biogen Idec CHOP=Cyclophosphamide, Doxorubicin, Vincristine and Prednisone; CVP=Cyclophosphamide, Vincristine and Prednisolone 16

17 Kadcyla Evaluating new treatment options in HER2-positive early breast cancer Phase/study HER2-positive neoadjuvant breast cancer KRISTINE HER2-positive early breast cancer high-risk patients KATHERINE Operable HER2-positive early breast cancer KAITLIN # of patients N=432 N=1,484 N=2,500 Before surgery patients will receive 6 cycles of: ARM A: Herceptin plus Perjeta plus docetaxel plus carboplatin ARM B: Kadcyla plus Perjeta After surgery patients will receive: ARM A: Herceptin plus Perjeta ARM B: Kadcyla plus Perjeta ARM A: Kadcyla 3.6mg/kg q3w ARM B: Herceptin Following surgery and antracycline-based therapy: ARM A: Herceptin 6mg/kg q3w plus Perjeta 420 mg/kg q3w plus chemo ARM B: Kadcyla 3.6mg/kg q3w plus Perjeta 420mg/kg q3w plus chemo Pathologic Complete Response (pcr) Invasive disease-free survival (IDFS) Invasive disease-free survival (IDFS) Status FPI Q FPI Q FPI Q In collaboration with ImmunoGen, Inc. 17

18 Kadcyla Evaluating new treatment options in HER2-positive breast and gastric cancer Phase/study Previously untreated HER2 pos. metastatic breast cancer MARIANNE Previously treated locally advanced or metastatic HER2-positive gastric cancer Phase II/III GATSBY HER2-positive advanced (2L+) NSCLC Phase II # of patients N=1,092 N=412 N=40 ARM A: Herceptin plus taxane ARM B: Kadcyla 3.6mg/kg q3w plus Perjeta ARM C: Kadcyla 3.6 mg/kg q3w plus placebo ARM A: Kadcyla 3.6mg/kg q3w ARM B: Kadcyla 2.4mg/kg weekly ARM C: docetaxel or paclitaxel Single-agent Kadcyla 3.6 mg/kg Progression-free survival assessed by IRF Phase II: Dose-finding : Overall survival Overall response rate and safety Status Study met non-inferiority, showing similar progression-free survival (PFS) among the three arms Q Study did not meet PFS superiority for Kadcyla-containing regimens Q Data to be presented at ASCO 2015 Recruitment completed Q Data expected in 2015 FPI Q In collaboration with ImmunoGen, Inc. ASCO=American Society of Clinical Oncology 18

19 MabThera/Rituxan Oncology development programme Phase/study Previously untreated chronic lymphocytic leukemia Phase Ib SAWYER Subcutaneous study Study being conducted ex-us # of patients N=225 Two-stage design: - Stage 1 (dose-finding, N=55) - Stage 2 (N=170): CLL dose confirmation: ARM A: MabThera IV plus chemotherapy (fludarabine and cyclophosphamide) ARM B: MabThera 1600mg SC plus chemotherapy (fludarabine and cyclophosphamide) Status Part 1: PK (dose selection) Part 2: PK of MabThera IV versus MabThera SC (arm A vs. arm B) Stage 2 data confirmed non-inferior PK and comparable safety/efficacy of MabThera 1600mg SC vs. MabThera IV Presented at ASH 2014 Filed in EU Q Subcutaneous MabThera : applies Enhanze technology, partnered with Halozyme ASH=American Society of Hematology 19

20 Perjeta First in a new class of HER dimerization inhibitors Phase/ study Neoadjuvant HER2-positive breast cancer Phase II NEOSPHERE Phase II TRYPHAENA Adjuvant HER2-positive breast cancer APHINITY # of patients N=417 N=225 N=4,803 Status ARM A: Herceptin plus docetaxel ARM B: Perjeta (840mg loading, 420mg q3w) plus Herceptin and docetaxel ARM C: Perjeta plus Herceptin ARM D: Perjeta plus docetaxel Pathologic complete response (pcr) Positive data presented at SABCS 2010 Biomarker data presented SABCS 2011 Survival data to be presented at ASCO 2015 ARM A: FEC followed by Taxane with Herceptin and pertuzumab (H+P given concurrently) ARM B: FEC followed by Taxane with Herceptin + pertuzumab (H+P given sequentially) ARM C: TCH + pertuzumab (H+P given concurrently) Safety Positive safety and efficacy data presented at SABCS 2011 FDA approval granted Q Filed in EU Q ARM A: Perjeta (840mg loading, 420 q3w) plus Herceptin for 52 weeks plus chemotherapy (6-8 cycles) ARM B: placebo plus Herceptin (52 weeks) plus chemotherapy (6-8 cycles) Invasive disease-free survival (IDFS) Recruitment completed Q Expect data in 2016 FEC = Fluorouracil, Epirubicin, and Cyclophosphamide; TCH = Docetaxel, Carboplatin, Herceptin; SABCS=San Antonio Breast Cancer Symposium; ASCO=American Society of Clinical Oncology 20

21 Perjeta First in a new class of HER dimerization inhibitors Second-line HER2- positive metastatic breast cancer Advanced HER2-positive gastric cancer Neoadjuvant/adjuvant HER2-positive breast cancer Phase/ study PHEREXA JACOB Phase II BERENICE # of patients N=450 N=780 N=400 ARM A: Herceptin plus Xeloda ARM B: Perjeta plus Herceptin and Xeloda ARM A: Perjeta (840mg loading, 420mg q3w) plus Herceptin and chemotherapy ARM B: placebo plus Herceptin and chemotherapy Neoadjuvant treatment: ARM A: ddac q2w x4 cycles followed by weekly paclitaxel for 12 weeks, with P+H x4 cycles ARM B: FEC+P+H x4 cycles followed by docetaxel+p+h x4 cycles Adjuvant treatment: P+H q3w to complete 1 year of HER2 therapy Hormonal and radiation therapy as indicated Progression-free survival Overall survival Safety Status Recruitment completed Q Expect data in 2015 FPI Q FPI Q ddac=dose-dense doxorubicin plus cyclophosphamide; FEC = Fluorouracil, Epirubicin, and Cyclophosphamide 21

22 Zelboraf A selective novel small molecule that inhibits mutant BRAF Adjuvant therapy in patients with resected cutaneous BRAF mutation positive melanoma Phase/study BRIM8 # of patients N= week treatment ARM A: Zelboraf 960mg bid ARM B: Placebo Disease-free survival Status FPI Q In collaboration with Plexxikon, a member of Daiichi Sankyo Group See also combinations with: cobimetinib (RG7421) and anti-pdl1 (RG7446) 22

23 Actemra/RoActemra Interleukin 6 receptor inhibitor Systemic sclerosis Giant Cell Arteritis Phase/study Phase II fasscinate Proof-of-concept study GiACTA # of patients N=86 N=250 Blinded 48-week treatment with weekly dosing: ARM A: Actemra SC 162mg ARM B: Placebo SC Open-label weekly dosing at weeks 49 to 96: Actemra SC 162mg Change in modified Rodnan skin score (mrss) at week 24 Safety Part 1: 52-week blinded period ARM A: Actemra SC 162mg qw + 26 weeks prednisone taper ARM B: Actemra SC 162mg q2w + 26 weeks prednisone taper ARM C: Placebo+ 26 weeks prednisone taper ARM D: Placebo+ 52 weeks prednisone taper Part II: 104-week open label extension patients in remission followed off of the study drug; Patients with active disease receive open label Actemra SC 162mg qw Proportion of patients in sustained remission at week 52 Status 48 week data presented at ACR 2014 and all key secondary s showed trend for improved efficacy FPI Q In collaboration with Chugai ACR=American College of Rheumatology 23

24 Pipeline summary Marketed products additional indications Global Development late-stage trials pred (Roche Pharma Research & Early Development) gred (Genentech Research & Early Development) Roche Group Q results Diagnostics Foreign exchange rate information 24

25 Alectinib (ALK inhibitor, RG7853, AF802) New CNS-active inhibitor of anaplastic lymphoma kinase Phase/study Treatment naïve ALK-positive advanced NSCLC ALEX ALK-positive crizotinib-naïve advanced NSCLC Phase I/II AF-001JP Japanese study # of patients N=286 N=70 ARM A: alectinib 600mg BID ARM A: crizotinib 250mg BID Part 1: Dose escalation monotherapy Part 2: Monotherapy, dose selected based on the results of Part 1 Progression-free survival Phase I: Determination of recommended dose Phase II: Safety and efficacy Status FPI Q Results published in Lancet Oncology 2013 Jun;14(7):590-8 Approved in Japan with brand name ALECENSA July 2014 In collaboration with Chugai 25

26 Alectinib (ALK inhibitor, RG7853, AF802) New CNS-active inhibitor of anaplastic lymphoma kinase Phase/study ALK-positive advanced NSCLC after progression on crizotinib treatment Phase I/II AF-002JG/NP28761 US study ALK-positive advanced NSCLC after progression on crizotinib treatment Phase I/II ACCALIA/NP28673 # of patients Phase I: N=36 Phase II: N=85 Part 1: Dose escalation monotherapy Part 2: Monotherapy, dose selected based on the results of Part 1 N=130 Part 1: Dose escalation monotherapy Part 2: Monotherapy, dose selected based on the results of Part 1 Phase I: Determination of recommended dose Phase II: Safety and efficacy Phase I: Determination of recommended dose Phase II: Safety and efficacy Status Phase I data presented at ECC 2013 Phase I full cohort including CNS data published in Lancet Oncology 2014, Sept.15(10): Phase II FPI Q analysis positive Q Data to be presented at ASCO 2015 Phase II FPI Q analysis positive Q Updated analysis in Q Data to be presented at ASCO 2015 Expect global filing in 2015 Breakthrough therapy designation granted by the FDA June 2013 In collaboration with Chugai ECC=European Cancer Congress; ASCO=American Society of Clinical Oncology 26

27 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy 1L non-squamous NSCLC PD-L1-selected patients 1L non-squamous NSCLC 1L non-squamous NSCLC Phase/study # of patients N=400 N=1200 N=550 ARM A: RG7446 monotherapy ARM B: carboplatin or cisplatin + pemetrexed ARM A: RG Avastin + paclitaxel + carboplatin ARM B: RG paclitaxel + carboplatin ARM C: Avastin + paclitaxel + carboplatin ARM A: RG nabpaclitaxel + carboplatin ARM B: nab-paclitaxel + carboplatin Progression-free survival Progression-free survival Progression-free survival Status Expect FPI Q FPI Q FPI Q

28 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy 1L squamous NSCLC PD-L1-selected patients 1L squamous NSCLC Phase/study # of patients N=400 N=1200 ARM A: RG7446 monotherapy ARM B: gemcitabine + cisplatin or carboplatin Progression-free survival ARM A: RG nabpaclitaxel + carboplatin ARM B: RG paclitaxel + carboplatin ARM C: nab-paclitaxel + carboplatin Progression-free survival Status Expect FPI Q Expect FPI Q

29 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy Locally advanced or Metastatic NSCLC 2 nd metastatic NSCLC line PD-L1 positive Locally advanced or metastatic NSCLC PD-L1 positive Locally advanced or metastatic NSCLC (2 nd /3 rd line) Non-small cell lung cancer Phase/study OAK Phase II FIR Phase II BIRCH Phase II POPLAR Phase I # of patients N=1100 N=130 N=635 N=287 N=32 ARM A: RG mg q3w ARM B: docetaxel Single arm study RG mg q3w Single arm study RG mg q3w ARM A: RG mg q3w ARM B: docetaxel RG7446 plus Tarceva 1 Overall survival Overall response rate Objective response rate Overall survival Safety Status FPI Q Recruitment completed Q Data to be presented at ASCO 2015 Recruitment completed Q Readout in 2015 Recruitment completed Q Data to be presented at ASCO 2015 FPI Q Tarceva is a registered trademark of OSI Pharmaceuticals, LLC, a subsidiary of Astellas US, LLC ASCO=American Society of Clinical Oncology 29

30 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy Previously Untreated Metastatic Triple Negative Breast Cancer Locally advanced or metastatic urothelial bladder cancer Locally advanced or metastatic urothelial bladder cancer Phase/study Phase II # of patients N=350 N=767 N=400 ARM A: RG nabpaclitaxel ARM B: placebo + nabpaclitaxel Patients who progressed on at least one platinumcontaining regimen will receive: ARM A: RG mg q3w ARM B: chemotherapy (vinflunine, paclitaxel or docetaxel) RG mg q3w Cohort 1: Treatment-naive and cisplatin-ineligible patients Cohort 2: Patients with disease progression following or during platinum-containing treatment Progression-free survival Overall survival Objective response rate Status Expect FPI H FPI Q Recruitment completed Q Readout in

31 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy Untreated advanced renal cell carcinoma Phase/study Phase II # of patients N=550 N=300 ARM A: RG7446 plus Avastin ARM B: sunitinib ARM A: RG7446 plus Avastin ARM B: RG7446; following PD: RG7446 plus Avastin ARM C: sunitinib; following PD: RG7446 plus Avastin Progression free survival Progression free survival Status Expect FPI Q Recruitment completed Q Readout in

32 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy Solid tumors Solid tumors Solid tumors Locally advanced or metastatic solid tumors Phase/study Phase I Phase I Phase I Phase I # of patients N=160 N=110 N=360 N=200 Part 1: sequential administration of RG7446 and RG7876 (CD40 imab) Part 2: concomitant administration of RG7446 and RG7876 Part 3: study drugs schedule in specific indication per Part 2 RG7446 in combination with RG7155 (anti-csf1r) Part 1: dose escalation Part 2: expansion Stage 1: Dose escalation of RG7446 plus RG7888 (anti-ox40) Stage 2: Expansion RG7446 plus RG7888 (anti- OX40) Safety Safety Safety Safety ARM A: RG7446 plus ipilimumab ARM B: RG7446 plus interferon alpha-2b Status FPI Q FPI Q Expect FPI Q FPI Q

33 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy Solid tumors Relapsed/Refractory follicular lymphoma and DLBCL Phase/study Phase I Phase I # of patients N=180 N=52 ARM A: RG Avastin ARM B: RG Avastin + FOLFOX ARM C: RG carboplatin + paclitaxel ARM D: RG carboplatin+ pemetrexed ARM E: RG carboplatin+ nab-paclitaxel ARM F: RG nab-paclitaxel Safety/PK Stage 1: safety evaluation RG7446 plus Gazyva Stage 2: expansion RG7446 plus Gazyva Safety Status FPI Q Chemo combination data in NSCLC to be presented at ASCO 2015 FPI Q

34 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy Solid tumors Previously untreated metastatic melanoma BRAF mutation positive Phase/study Phase I Phase I # of patients N=180 N=44 ARM A: RG Avastin ARM B: RG Avastin + FOLFOX ARM C: RG carboplatin + paclitaxel ARM D: RG carboplatin+ pemetrexed ARM E: RG carboplatin+ nabpaclitaxel ARM F: RG nab-paclitaxel Dose-finding study of RG Zelboraf 1 and RG Zelboraf 1 + cobimetinib 2 combinations Safety/PK Safety/PK Status FPI Q Chemo combination data in NSCLC to be presented at ASCO 2015 FPI Q Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group; 2 Cobimetinib in collaboration with Exelixis 34

35 Anti-PDL1 (MPDL3280A, RG7446) Novel approach in cancer immunotherapy Previously untreated metastatic melanoma BRAF mutation positive Solid tumors Previously untreated metastatic melanoma BRAF mutation positive Phase/study Phase I Phase I Phase I # of patients N=44 N=90 N=344 Dose-finding study of RG Zelboraf 1 and RG Zelboraf 1 + cobimetinib 2 combinations ARM A: Dose-finding RG7446 plus cobimetinib ARM B: Dose-expansion - RG7446 plus cobimetinib Dose escalation study Safety/PK Safety Safety/PK Status FPI Q FPI Q FPI Q Initial efficacy data presented at ASCO 2013 Updated data presented at ECC 2013 Data from bladder cohort presented at ASCO and ESMO 2014 Data from TNBC cohort presented at AACR 2015 Updated lung and bladder data to be presented at ASCO Zelboraf in collaboration with Plexxikon, a member of Daiichi Sankyo Group; 2 Cobimetinib in collaboration with Exelixis ASCO=American Society of Clinical Oncology; ECC=European Cancer Congress; AACR=American Association for Cancer Research ESMO=European Society for Medical Oncology 35

36 Cobimetinib (RG7421, GDC-0973) Selective small molecule inhibitor of mitogenactivated protein kinase kinase Phase/study Previously untreated metastatic melanoma BRAF mutation positive cobrim First-line metastatic triple negative breast cancer Phase II # of patients N=495 N=112 ARM A: Zelboraf 1 plus cobimetinib ARM B: Zelboraf 1 plus placebo ARM A: cobimetinib plus paclitaxel ARM B: placebo plus paclitaxel Progression-free survival Progression-free survival, safety Status met Q Data presented at ESMO and SMR 2014 Results published NEJM 2014 Nov 13;371(20): Filed in EU Q Filed in US Q Priority review granted Q Updated data to be presented at ASCO 2015 FPI Q In collaboration with Exelixis 1 Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group; ESMO=European Society for Medical Oncology; SMR=Society for Melanoma Research; NEJM=New England Journal of Medicine 36

37 Cobimetinib (RG7421, GDC-0973) Selective small molecule inhibitor of mitogenactivated protein kinase kinase Locally advanced or metastatic tumors Previously untreated metastatic melanoma BRAF mutation positive Locally advanced or metastatic tumors with mutant KRAS Phase/study Phase I Phase I Phase I # of patients N=90 N=44 N=50 ARM A: Dose-finding - cobimetinib plus RG7446 (anti- PDL1) ARM B: Dose-expansion - cobimetinib plus RG7446 (anti- PDL1) Dose-finding study of RG7446+Zelboraf 1 and RG7446+Zelboraf+ cobimetinib combinations Dose finding of cobimetinib plus RG7597 (anti-her3/egfr DAF) Safety Safety/PK Safety Status FPI Q FPI Q FPI Q In collaboration with Exelixis 1 Zelboraf In collaboration with Plexxikon, a member of Daiichi Sankyo Group 37

38 Polatuzumab vedotin (RG7596) Antibody drug conjugate targeting CD79b for the treatment of B-cell malignancies Non-Hodgkin's lymphoma Non-Hodgkin s lymphoma Relapsed or Refractory follicular lymphoma and DLBCL Phase Phase II ROMULUS Phase Ib/II Phase Ib/II # of patients N=228 N=90 N=224 ARM A: pinatuzumab vedotin plus Rituxan ARM B: polatuzumab vedotin plus Rituxan ARM C: polatuzumab vedotin plus Gazyva PhIb: dose escalation PhII: polatuzumab vedotin in combinaiton with Rituxan or Gazyva and CHP non-randomized PIb: dose escalation PhII: polatuzumab vedotin + BR vs. BR PhII expansion: polatuzumab vedotin +Gazyva non-randomized Safety and anti-tumor activity Safety Safety and response by PET/CT Status Recruitment in arms A&B completed Q Updated data presented at ASH 2014 FPI in Gazyva arm C Q Updated data to be presented at ASCO 2015 FPI Q FPI Q In collaboration with Seattle Genetics ASH=American Society of Hematology; ASCO=American Society of Clinical Oncology BR=bendamustine and Rituxan; CHP=Cyclophosphamide, Hydroxydoxorubicin, Prednisone 38

39 Taselisib (RG7604, GDC-0032) Mutant-selective PI3 kinase inhibitor Phase HER2-negative ER-positive metastatic breast caner patients who progressed after aromatase inhibitor therapy SANDPIPER Neoadjuvant HER2-negative ERpositive breast cancer Phase II LORELEI # of patients N=600 N=330 ARM A: taselisib plus Fulvestrant ARM B: placebo plus Fulvestrant ARM A: taselisib plus letrozole ARM B: placebo plus letozole Progression-free survival Response rate and pcr Status Expect FPI Q FPI Q

40 Taselisib (RG7604, GDC-0032) Beta isoform sparing PI3 kinase inhibitor targeting commonly mutated oncogene x Solid tumors and HER2-negative HR-positive breast cancer HER2-negative HR-positive locally recurrent or metastatic breast cancer PI3KCAmut-pos. 2L squamous NSCLC Lung Master Protocol Phase Phase I/II Phase I Phase II Lung-MAP # of patients N=320 N=65 N=120 Phase I taselisib taselisib plus letrozole or fulvestrant taselisib plus docetaxel taselisib plus paclitaxel taselisib vs. chemo Phase II taselisib (multiple doses) plus letrozole or fulvestrant Safety/PK/efficacy Safety Progression-free survival Status Recruitment completed Q Updated data presented at SABCS 2014 FPI Q FPI Q SABCS=San Antonio Breast Cancer Symposium 40

41 Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor Untreated CLL patients with coexisting medical conditions Relapsed or Refractory CLL Relapsed or Refractory CLL with 17p deletion Phase/study CLL14 MURANO Phase II # of patients N=432 N=370 N=100 ARM A: venetoclax plus Gazyva ARM B: chlorambucil plus Gazyva ARM A: venetoclax plus Rituxan ARM B: Rituxan plus bendamustine Single-agent venetoclax Progression-free survival Progression-free survival Safety/MTD Status FPI Q FPI Q Recruitment completed Q Data expected in 2015 Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) CLL=Chronic Lymphocytic Leukemia; NHL=Non-Hodgkin's Lymphoma; SLL=Small Lymphocytic Lymphoma ASCO=American Society of Clinical Oncology 41

42 Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor Phase/stud y # of patients Relapsed or Refractory CLL Relapsed CLL and SLL Relapsed or Refractory or previously untreated CLL Relapsed or Refractory or previously untreated CLL Phase II Phase Ib Phase Ib Phase Ib N=40 N=50 N=70 N=74 venetoclax after ibrutinib therapy venetoclax after idelalisib therapy Dose-escalation study in combination with MabThera/Rituxan venetoclax in combination with MabThera/Rituxan and bendamustine venetoclax in combination with Gazyva Overall response rate Safety/MTD Safety/MTD Safety/MTD Status FPI Q Recruitment completed Q Data presented at ASCO 2014 FPI Q FPI Q Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) CLL=Chronic Lymphocytic Leukemia; NHL=Non-Hodgkin's Lymphoma; SLL=Small Lymphocytic Lymphoma ASCO=American Society of Clinical Oncology 42

43 Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor Relapsed or Refractory follicular non-hodgkin s lymphoma Front-line DLBCL Relapsed or Refractory NHL Relapsed or Refractory CLL and NHL Phase/study Phase II CONTRALTO Phase I/II CAVALLI Phase I Phase I # of patients N=156 N=230 N=40 N=211 ARM A: venetoclax plus Rituxan ARM B: venetoclax plus Rituxan plus bendamustine ARM C: Rituxan plus bendamustine Dose finding: ARM A: venetoclax+r- CHOP ARM B: venetoclax+g- CHOP Expansion: venetoclax+r/g-chop Dose escalation of venetoclax in combination with Rituxan and bendamustine Dose-escalation study Overall response rate Safety and efficacy Overall response rate Safety/PK/Response rate Status FPI Q FPI Q FPI Q Study resumed Q FPI Q Updated CLL, SLL and NHL (DLBCL and FL) data presented at ASCO 2014 Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) ASCO=American Society of Clinical Oncology 43

44 Venetoclax (RG7601, ABT-199/GDC-0199) Novel small molecule Bcl-2 selective inhibitor Relapsed or refractory multiple myeloma Acute myelogenous leukemia (AML) Phase/study Phase I Phase I Phase II Phase Ib # of patients N=30 N=30 N=54 N=89 Patients receiving Bortezomib and Dexamethasone as standard therapy: Dose escalation cohort: venetoclax+bortezomib+de xamethasone Safety expansion cohort: venetoclax+bortezomib+de xamethasone Dose escalation cohort Safety expansion cohort Dose escalation of venetoclax Safety/MTD Safety/MTD Overall response rate Safety Status FPI Q FPI Q FPI Q Data presented at ASH 2014 venetoclax (dose escalation) +decitabine venetoclax (dose escalation) +azacitidine FPI Q Joint project with AbbVie in collaboration with WEHI (The Walter and Eliza Hall Institute) 44

45 Factor IXa/X bispecific (RG6013, ACE910) Factor VIII mimetic for treatment of hemophilia A Hemophilia A Phase/study Phase I Study in Japan Phase I/II Study in Japan # of patients N=82 N 18 Enrolled 64 HVs and 18 patients Extension study in patients from phase 1 Exploratory efficacy and safety Exploratory efficacy and safety Status Recruitment completed Q Data presented at ASH 2014 Recruitment completed Q In collaboration with Chugai ASH=American Society of Hematology 45

46 Bitopertin (GlyT-1, RG1678) A small molecule first-in-class glycin reuptake inhibitor (GRI) Obsessive-compulsive disorder Phase/study Phase II SKYLYTE # of patients N=99 16-week treatment period Background therapy of selective serotonin reuptake inhibitors (SSRI) ARM A: bitopertin daily (30 mg) ARM B: bitopertin daily (10 mg) ARM C: placebo Change in total score on Yale-Brown Obsessive Compulsive Scale Status Enrollment completed Q

47 Gantenerumab (RG1450) Fully human monoclonal antibody against amyloid-beta Prodromal Alzheimer s Disease Mild Alzheimer s Disease Phase/study Phase II/III SCarlet RoAD Marguerite Road # of patients N=799 N=1,000 Status 104-week subcutaneous treatment period ARM A: gantenerumab (225 mg) ARM B: gantenerumab (105 mg) ARM C: placebo Change in CDR-SOB at 2 years Sub-study: change in brain amyloid by PET at 2 years Phase I PET data: Archives of Neurology 2012 Feb;69(2): Enrollment completed Q Dosing stopped due to futility Q week subcutaneous treatment period ARM A: gantenerumab ARM B: placebo Change in ADAS-Cog and ADCS-ADL at 2 years (co-primary) FPI Q In collaboration with Morphosys CDR-SOB=Clinical Dementia Rating scale Sum of Boxes 47

48 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin Ulcerative colitis patients who are TNF naïve Phase/study HIBISCUS I Induction study HIBISCUS II Induction study GARDENIA Sustained remission study # of patients N=350 N=350 N=720 ARM A: etrolizumab 105mg SC q4w + adalimumab placebo ARM B: etrolizumab placebo + adalimumab ARM C: etrolizumab placebo + adalimumab placebo Induction of remission compared with placebo as determined by the Mayo Clinic Score (MCS) at week 10 ARM A: etrolizumab 105mg SC q4w + adalimumab placebo ARM B: etrolizumab placebo + adalimumab ARM C: etrolizumab placebo + adalimumab placebo Induction of remission compared with placebo as determined by the Mayo Clinic Score (MCS) at week 10 Status FPI Q FPI Q FPI Q Time on treatment 54 weeks ARM A: etrolizumab 105mg SC q4w + placebo IV ARM B: placebo SC q4w + adalimumab SC Proportion of patients in sustained clinical remission as determined by Mayo Clinic Score (MCS) at weeks 10, 30 and 54 48

49 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin Phase/study UC patient who are TNF naïve and refractory or intolerant to immunosuppressant and/or corticosteroid treatment LAUREL Maintenance study UC patient who are refractory or intolerant of TNF inhibitors HICKORY Induction and maintenance study # of patients N=350 N=800 Induction phase: ARM A: open label etrolizumab 105mg SC q4w Maintenance study: ARM B: etrolizumab 105mg SC q4w ARM C: placebo Cohort 1 (open-label): ARM A: etrolizumab induction + placebo maintenance ARM B: etrolizumab induction + maintenance Cohort 2 (blinded): ARM A: etrolizumab induction + maintenance ARM B: placebo induction + maintenance Maintenance of remission (at week 62) among randomized patients in remission at Week 10 as determined by the Mayo Clinic Score (MCS) Status FPI Q FPI Q Clinical Remission (Mayo Clinic Score, MCS) at Week 14 Remission maintenance (by MCS, at Week 66) among patients with remission at Week 14 UC=ulcerative colitis 49

50 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin Moderate to severe ulcerative colitis Moderate to severe ulcerative colitis Phase/study Phase II SPRUCE Open label extension study COTTONWOOD Open label extension study # of patients N=116 N=2,600 Patients who were enrolled in EUCALYPTUS study and meet enrollment criteria will receive etrolizumab 105 sc q4w Patients who were previously enrolled in etrolizumab phase III studies and meet enrollment criteria will receive etrolizumab 105 sc q4w Safety Long-term efficacy as determined by partial Mayo Clinic Score (pmcs) Incidence of adverse events Status Recruitment completed FPI Q

51 Etrolizumab (RG7413) A humanized monoclonal antibody against beta 7 integrin Phase/study Moderately to severely active Crohn's disease BERGAMOT Moderately to severely active Crohn's disease JUNIPER # of patients N=1,250 N=1,250 ARM A: etrolizumab SC 210 mg (induction only) ARM B: etrolizumab SC 105 mg and maintainance ARM C: placebo Etrolizumab SC 105mg q4w Induction and maintenance of clinical remission Safety Status FPI Q Expect FPI Q

52 HCV: Danoprevir (RG7227) IFN-based triple regimen for treatment-naïve patients of Asian origin conducted in China Treatment-naïve patients of Asian origin with chronic hepatitis C genotype 1 with or without cirrhosis Phase/study Phase II DAPSANG # of patients N=61 Without cirrhosis: ARM A: Danoprevir 125 mg bid + Ritonavir 100mg bid+ Pegasys + Copegus for 12 weeks With compensated cirrhosis: ARM B: Danoprevir 125 mg bid + Ritonavir 100mg bid+ Pegasys + Copegus for 24 weeks Safety Status Recruitment completed Q Results presented at APASL 2015 In collaboration with Ascletis APASL=Asian Pacific Association for the Study of the Liver 52

53 Lampalizumab (RG7417) Antibody fragment to selectively block activation of alternative complement pathway Geographic atrophy (GA) secondary to age-related macular degeneration Phase/study CHROMA SPECTRI Phase II # of patients N=936 N=936 N=100 ARM A: lampalizumab 10mg q4w ARM B: lampalizumab 10mg q6w ARM C: placebo ARM A: lampalizumab 10mg q4w ARM B: lampalizumab 10mg q6w ARM C: placebo ARM A: lampalizumab 10mg q2w ARM B: lampalizumab 10mg q4w ARM C: placebo : change in GA area Secondary: change in BCVA and in additional measures of visual function Status FPI Q presented at EURETINA 2014 Fast track designation received Q : change in GA area Secondary: change in BCVA and in additional measures of visual function FPI Q presented at EURETINA 2014 Fast track designation received Q Change in GA area FPI Q EURETINA=European Society of Retina Specialists 53

54 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13 Severe uncontrolled adult asthma Phase/study # of patients Adult patients whose asthma is uncontrolled with inhaled corticosteroids and a second controller medication LAVOLTA I N=1,050 Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks safety follow-up ARM A: lebrikizumab high dose ARM B: lebrikizumab low dose ARM C: placebo Patients will be tested for periostin level LAVOLTA II N=1,050 Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks safety follow-up ARM A: lebrikizumab high dose ARM B: lebrikizumab low dose ARM C: placebo Patients will be tested for periostin level Rate of asthma exacerbations during the 52-week placebo-controlled period Rate of asthma exacerbations during the 52-week placebo-controlled period Status Enrollment completed Q Expect data in 2016 Enrollment completed Q Expect data in

55 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13 Phase/study Adolescent patients whose asthma is uncontrolled with inhaled corticosteroids and a second controller medication ACOUSTICS Idiopathic pulmonary fibrosis Phase II RIFF # of patients N=375 N=250 Subcutaneous lebrikizumab q4w on top of SOC for 52 weeks with 52 week double-blind active treatment extension ARM A: lebrikizumab high dose, week or week ARM B: lebrikizumab low dose, week or week ARM C: placebo, week 1-52 Rate of asthma exacerbations during the 52- week placebo-controlled period ARM A: lebrikizumab SC q4w ARM B: placebo ARM C: lebrikizumab SC q4w + Esbriet ARM D: Esbriet Progression-free survival Status FPI Q FPI Q (arms A&B) Expect FPI Q (arms C&D) SOC=Standard of Care; OCS=Oral Corticosteroids 55

56 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13 Phase/study Adult asthma Phase II VOCALS Adult asthma mild-to-moderate patients STRETTO # of patients N=225 N=300 ARM A: lebrikizumab high dose SC q4w ARM B: lebrikizumab low dose SC q4w ARM C: placebo ARM A: lebrikizumab SC q4w ARM B: placebo ARM C: Montelukast Relative change in OCS dose at week 44 Absolute change in FEV1 at week 12 Status FPI Q FPI Q

57 Lebrikizumab (RG3637) A humanized monoclonal antibody designed to bind specifically to IL-13 Phase/study Adult asthma Phase II CLAVIER Mechanistic biomarker study Moderate-to-severe atopic dermatitis Phase II # of patients N=120 N=200 ARM A: lebrikizumab SC q4w ARM B: placebo Patients on topical corticosteroids ARM A: lebrikizumab dose 1 ARM B: lebrikizumab dose 2 ARM C: lebrikizumab dose 3 ARM D: placebo Relative change in airway inflammation (eosinophils/mm2) at week 12 Percentage of patients achieving a 50% reduction in Eczema Area and Severity Index (EASI) score (EASI-50) from baseline to week 12 Status FPI Q Expect FPI Q

58 Ocrelizumab (RG1594) 2nd generation anti-cd20 monoclonal antibody Relapsing multiple sclerosis (RMS) progressive multiple sclerosis (PPMS) Phase/study OPERA I OPERA II ORATORIO # of patients N=800 N=800 N= week treatment period: ARM A: Ocrelizumab 2x 300 mg iv followed by 600 mg iv every 24 weeks ARM B: Interferon -1a 96-week treatment period: ARM A: Ocrelizumab 2x 300 mg iv followed by 600 mg iv every 24 weeks ARM B: Interferon -1a 120-week treatment period: ARM A: Ocrelizumab 2x 300 mg iv every 24 weeks ARM B: Placebo Annualized relapse rate at 96 weeks versus Rebif Annualized relapse rate at 96 weeks versus Rebif Sustained disability progression versus placebo by Expanded Disability Status Scale (EDSS) Status Enrollment completed Q Expect data in H Enrollment completed Q Expect data in H Enrollment completed Q Expect data in H